GSK and Impax Pharmaceuticals Terminate Their Collaboration on IPX066
News May 07, 2013
GlaxoSmithKline (GSK) plc and Impax Pharmaceuticals have announced that they are terminating their collaboration for the development and commercialization of IPX066 outside the United States and Taiwan.
IPX066 is a carbidopa-levodopa extended release product in Phase III development for the symptomatic treatment of Parkinson’s disease and is not approved anywhere in the world.
Under the terms of the agreement entered into in December 2010, GSK’s right to develop and commercialize IPX066 outside the United States and Taiwan will transfer back to Impax with effect at the end of July 2013.
The decision has been reached because of delays in the anticipated regulatory approval and launch dates in countries in which GSK has rights to commercialize the product.
Impax will take over development of IPX066 on a worldwide basis while seeking the opportunity to partner its rights in markets outside of the United States.
GSK remains committed to discovering, developing and delivering innovative medicines for patients with Parkinson’s disease.
GlaxoSmithKline - one of the world’s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Novel Green Chemistry Method Improves Pharmaceutical Manufacturing EfficiencyNews
About 70 percent of pharmaceuticals are manufactured using palladium-driven catalytic processes that are either fast or efficient - but not both. Researchers have now developed a green chemistry method that combines aspects of both processes to improve efficiency at a minimal cost of processing time.READ MORE
Enamine and BioSolveIT Launch the World's Largest Searchable Chemical Space for Novel Compound SourcingNews
REAL Space Navigator offers access to over 640 million pharma-oriented compounds.READ MORE